EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAPP)

被引：0
|
作者：
Cardona, A. [1 ]
Ruiz-Patino, A. [1 ]
Castro, C. [1 ]
Rojas, L. [2 ]
Arrieta, O. [3 ,4 ]
Zatarain-Barron, Z. [5 ,6 ]
Carranza, H. [1 ]
Vargas, C. [1 ]
Otero, J. [1 ]
Corrales, L. [7 ]
Martin, C. [8 ]
Rosell, R. [9 ]
机构：
[1] Fdn Clin & Appl Canc Res Ficmac, Clin & Translat Oncol Grp, Bogota, Colombia
[2] Clin Univ Colombia, Med Oncol, Bogota, Colombia
[3] Natl Canc Inst, Unidad Func Oncol Torac, Mexico City, DF, Mexico
[4] Natl Canc Inst, Lab Med Personalizada, Mexico City, DF, Mexico
[5] Inst Nacl Cancerol, Thorac Oncol Unit, Mexico City, DF, Mexico
[6] Inst Nacl Cancerol, Lab Personalized Med, Mexico City, DF, Mexico
[7] Hosp San Jose, Clin Oncol, San Jose, Costa Rica
[8] Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina
[9] Germans Trias & Pujol Hlth Sci Inst & Hosp, Canc Biol & Precis Med Program, Catalan Inst Oncol, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
EGFR mutations; EGFR amplification; Adenocarcinoma;
D O I：
10.1016/j.jtho.2018.08.1406
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.13-11
引用
收藏
页码：S802 / S802
页数：1
相关论文
共 50 条
  • [1] EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP)
    Cardona, Andres
    Arrieta, Oscar
    Corrales, Luis
    Rojas, Leonardo
    Cuello, Mauricio
    Martin, Claudio
    Carranza, Hernan
    Vargas, Carlos
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S523 - S523
  • [2] EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients
    Ruiz-Patino, A.
    Castro, C.
    Ricaurte, L.
    Cardona, A.
    Rojas, L.
    Zatarain-Barron, Z.
    Wills, B.
    Reguart, N.
    Carranza, H.
    Vargas, C.
    Otero, J.
    Corrales, L.
    Martin, C.
    Archila, P.
    Rodriguez, J.
    Avila, J.
    Bravo, M.
    Pino, L.
    Rosell, R.
    Arrieta, O.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S161 - S162
  • [3] EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)
    Alejandro Ruiz-Patiño
    Christian David Castro
    Luisa María Ricaurte
    Andrés F. Cardona
    Leonardo Rojas
    Zyanya Lucia Zatarain-Barrón
    Beatriz Wills
    Noemí Reguart
    Hernán Carranza
    Carlos Vargas
    Jorge Otero
    Luis Corrales
    Claudio Martín
    Pilar Archila
    July Rodriguez
    Jenny Avila
    Melissa Bravo
    Luis Eduardo Pino
    Rafael Rosell
    Oscar Arrieta
    Targeted Oncology, 2018, 13 : 621 - 629
  • [4] EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)
    Ruiz-Patino, Alejandro
    David Castro, Christian
    Maria Ricaurte, Luisa
    Cardona, Andres F.
    Rojas, Leonardo
    Lucia Zatarain-Barron, Zyanya
    Wills, Beatriz
    Reguart, Noemi
    Carranza, Hernan
    Vargas, Carlos
    Otero, Jorge
    Corrales, Luis
    Martin, Claudio
    Archila, Pilar
    Rodriguez, July
    Avila, Jenny
    Bravo, Melissa
    Eduardo Pino, Luis
    Rosell, Rafael
    Arrieta, Oscar
    TARGETED ONCOLOGY, 2018, 13 (05) : 621 - 629
  • [5] Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients
    Shan, Ling
    Wang, Ziping
    Guo, Lei
    Sun, Hongyan
    Qiu, Tian
    Ling, Yun
    Li, Wenbin
    Li, Lin
    Liu, Xiuyun
    Zheng, Bo
    Lu, Ning
    Ying, Jianming
    LUNG CANCER, 2015, 89 (03) : 337 - 342
  • [6] Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation
    de Lima Araujo, Luiz H.
    da Silveira, Juliana S.
    Baldotto, Clarissa S.
    Zukin, Mauro
    Ferreira, Carlos G.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : 1059 - 1060
  • [7] Erlotinib in lung cancer patients with EGFR mutations and amplification; a focus on toxicity
    Ruder, Aimee D.
    Blazer, Marlo
    Poirier, Jessica
    Zhao, Weiqiang
    Villalona-Calero, Miguel A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S710 - S711
  • [8] Clinical Features and Progression Free Survival of Lung Adenocarcinoma Patients with EGFR sensitizing mutations with Dose Reduction of Afatinib
    Angasreni, W.
    Andarini, S. L.
    Zaini, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S641 - S642
  • [9] Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations
    Hsu, W. -H.
    Hsu, C. -C.
    Yang, J. C. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S254 - S255
  • [10] Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (07) : E57 - E58
12345